ERBB3 and familial pancreatic carcinoma: Hence, the change in the total level of EGFR and HER2 in response to canertinib and afatinib treatment, predicts a possible inactivation of HER3 and disabling of HER4 mediated signaling events such as proliferation and apoptosis in pancreatic cancer cells.